KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Accounts Payables (2017 - 2025)

Amneal Pharmaceuticals has reported Accounts Payables over the past 9 years, most recently at $38.8 million for Q4 2025.

  • Quarterly results put Accounts Payables at $38.8 million for Q4 2025, up 3122.57% from a year ago — trailing twelve months through Dec 2025 was $38.8 million (up 3122.57% YoY), and the annual figure for FY2025 was $38.8 million, up 3122.57%.
  • Accounts Payables for Q4 2025 was $38.8 million at Amneal Pharmaceuticals, up from $40000.0 in the prior quarter.
  • Over the last five years, Accounts Payables for AMRX hit a ceiling of $666.8 million in Q2 2025 and a floor of $2000.0 in Q4 2023.
  • Median Accounts Payables over the past 5 years was $525.3 million (2021), compared with a mean of $328.4 million.
  • Biggest five-year swings in Accounts Payables: plummeted 100.0% in 2023 and later surged 33340750.0% in 2025.
  • Amneal Pharmaceuticals' Accounts Payables stood at $525.3 million in 2021, then increased by 2.45% to $538.2 million in 2022, then plummeted by 100.0% to $2000.0 in 2023, then soared by 60150.0% to $1.2 million in 2024, then soared by 3122.57% to $38.8 million in 2025.
  • The last three reported values for Accounts Payables were $38.8 million (Q4 2025), $40000.0 (Q3 2025), and $666.8 million (Q2 2025) per Business Quant data.